Condition: Breast Cancer · Sponsor: Massachusetts General Hospital
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
This description comes directly from the study's public registry record.
Neelima Vidula, MD · 617-724-4000 · nvidula@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| UCSF Medical Center-Mission Bay/Benioff Children's Hospital | San Francisco, California, United States | Recruiting |
| Emory University Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital Cancer Center | Boston, Massachusetts, United States | Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03990896